Breathe Well Live Well
|
Elderly asthma patients had greater airway involvement than younger patients
Healio Researchers in Japan conducted a retrospective analysis on 45 elderly patients (aged more than 65 years) with asthma (mean age, 73.1 years; 34 women; median disease duration, 12.7 years) and 67 nonelderly patients with asthma (mean age, 48.6 years; … |
View full post on asthma – Google News
Condition: Asthma
Intervention:
Sponsor: Chiesi Farmaceutici S.p.A.
Not yet recruiting – verified April 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
 |
Related Articles |
The Involvement of Phospholipases A 2 in Asthma and Chronic Obstructive Pulmonary Disease.
Mediators Inflamm. 2013;2013:793505
Authors: Pniewska E, Pawliczak R
Abstract
The increased morbidity, mortality, and ineffective treatment associated with the pathogenesis of chronic inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD) have generated much research interest. The key role is played by phospholipases from the A2 superfamily: enzymes which are involved in inflammation through participation in pro- and anti-inflammatory mediators production and have an impact on many immunocompetent cells. The 30 members of the A2 superfamily are divided into 7 groups. Their role in asthma and COPD has been studied in vitro and in vivo (animal models, cell cultures, and patients). This paper contains complete and updated information about the involvement of particular enzymes in the etiology and course of asthma and COPD.
PMID: 24089590 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Anti-inflammatory and antinociceptive effects of salbutamol on acute and chronic models of inflammation in rats: involvement of an antioxidant mechanism.
Mediators Inflamm. 2012;2012:438912
Authors: Uzkeser H, Cadirci E, Halici Z, Odabasoglu F, Polat B, Yuksel TN, Ozaltin S, Atalay F
Abstract
The possible role of ?-2 adrenergic receptors in modulation of inflammatory and nociceptive conditions suggests that the ?-2 adrenergic receptor agonist, salbutamol, may have beneficial anti-inflammatory and analgesic effects. Therefore, in this study, we induced inflammatory and nociceptive responses with carrageenan-induced paw edema or cotton-pellet-induced granuloma models, both of which result in oxidative stress. We hypothesized that salbutamol would prevent inflammatory and nociceptive responses by stimulating ?-2 adrenergic receptors and the prevention of generation of ROS during the acute inflammation process in rats. Both doses of salbutamol used in the study (1 and 2?mg/kg) effectively blocked the acute inflammation and inflammatory nociception induced by carrageenan. In the cotton-pellet-induced granuloma test, both doses of salbutamol also significantly decreased the weight of granuloma tissue on the cotton pellets when compared to the control. Anti-inflammatory and analgesic effects of salbutamol were found to be comparable with those of indomethacin. Salbutamol decreased myeloperoxidase (MPO) activity and lipid peroxidation (LPO) level and increased the activity of superoxide dismutase (SOD) and level of glutathione (GSH) during the acute phase of inflammation. In conclusion, salbutamol can decrease acute and chronic inflammation, possibly through the stimulation of ?-2 adrenergic receptors. This anti-inflammatory effect may be of significance in asthma treatment, where inflammation also takes part in the etiopathology. This study reveals that salbutamol has significant antioxidative effects, which at least partially explain its anti-inflammatory capabilities. These findings presented here may also shed light on the roles of ?-2 adrenergic receptors in inflammatory and hyperalgesic conditions.
PMID: 22665951 [PubMed – in process]
View full post on pubmed: asthma